RxDoctor Payments Data

Madhavi Devaraju, MD

Family Medicine · Alpharetta, GANPI 1699969949

Payments from drug & device makers

$4,523in general payments, 2019–2025

Across 237 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$778
  • Lilly USA, LLC$365
  • AstraZeneca$360
  • Sanofi-aventis U.S. LLC$291
  • Amgen$204
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,40397%
  • Education$1203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,523 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$43,584
Medicare patients
113
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$52,334
FarxigaDapagliflozin Propanediol42$43,624
RybelsusSemaglutide12$24,280
JanumetSitagliptin Phos/Metformin Hcl19$23,039
LinzessLinaclotide20$14,627
VascepaIcosapent Ethyl16$6,036
BelsomraSuvorexant11$4,972
Novolog FlexpenInsulin Aspart18$3,805
SynthroidLevothyroxine Sodium29$2,214
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,757
Atorvastatin Calcium216$1,003
Levothyroxine Sodium138$918
Omeprazole91$887
Propranolol Hcl ErPropranolol Hcl18$831
Rosuvastatin Calcium84$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$778$76,61464 claims
AstraZenecaFarxiga$360$43,62442 claims
MerckJanumet, Belsomra$99$28,01130 claims
AbbVieLinzess, Synthroid$1,305$16,84149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →